NASHVILLE, Tenn. / Oct 13, 2023 / Business Wire / Leading health and well-being company Humana Inc. (NYSE: HUM) today announced that, for the third consecutive year and the fourth time overall, its statewide Humana HMO Medicare Advantage plan in Tennessee has achieved the highest possible 5-star rating from the Centers for Medicare & Medicaid Services (CMS). The 5-star Cariten Health Plan Inc. HMO plan is offered in all of Tennessee’s 95 counties.
The Tennessee HMO plan is one of four Humana contracts that received a 5-star rating for 2024 on CMS’s 5-star rating system. The four plans combined cover approximately 790,000 members across the country, more than doubling the number of Humana members in 5-star plans in 2023.
“This top rating is a testament to the work our Tennessee team puts in every day to deliver the best member experience,” said Matt Berger, Humana’s Medicare President for Tennessee. “We’re grateful, too, to the top-tier value-based providers and the excellent brokers we partner with to look out for the best interests of the 166,500 members enrolled in this plan.”
Barry W., a Humana Medicare Advantage member in Knoxville, has found the pharmacy benefits included in his plan especially helpful.
“Humana has helped me streamline my medications through the pharmacy and this has made the recording and delivery process easier,” said Barry. “They have also introduced me to ways I can better afford my medicines—some even being free, if I qualify.”
About Medicare Advantage Enrollment
The Medicare Advantage and Prescription Drug Plan Annual Election Period (AEP) begins Oct. 15 and continues through Dec. 7. During this enrollment period, people eligible for Medicare can choose Medicare Advantage and Prescription Drug Plans for the upcoming year – with coverage that takes effect Jan. 1.
People eligible for Medicare may make a one-time election to enroll in a plan offered by an MA organization with a Star Rating of 5 stars during the year in which that plan has the 5-star overall performance rating, provided the enrollee meets the other requirements to enroll in that plan. This 5-star special election is available Dec. 8 through Nov. 30 of the following year.
For more information about Humana’s 2024 Medicare offerings, visit Humana.com/Medicare or call toll-free 1-800-706-1368 (TTY: 711). Licensed sales agents are available 8 a.m. to 8 p.m. local time, seven days a week.
About CMS Star Ratings
The CMS rating system measures the excellence of Medicare plans nationally each year. A plan may receive a rating between one and five stars, with five stars representing the highest rating. CMS uses information from member-satisfaction surveys, health plans, and health care providers to assign overall Star Ratings to plans. The rating system uses more than 40 different quality measures across nine categories, including:
Additional information about the CMS Star Ratings can be found at: www.medicare.gov.
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
Additional Information
Humana is a Medicare Advantage HMO organization with a Medicare contract. Enrollment in any Humana plan depends on contract renewal. Every year, Medicare evaluates plans based on a 5-star rating system. Other providers are available in the Humana network.
Last Trade: | US$275.67 |
Daily Change: | -7.47 -2.64 |
Daily Volume: | 1,539,742 |
Market Cap: | US$33.190B |
November 12, 2024 October 30, 2024 October 24, 2024 October 23, 2024 August 19, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB